

Market Outlook

The Nifty 50 closed at 26,013, recording a positive start to the week with a decisive close above the 26,000 mark. In the derivatives segment, fresh Put OI build-up at the 25,900 strike indicates a strong immediate support zone, strengthening the potential for an upside move toward the 26,200 and 26,300 levels, aligned with major Call OI buildup. On the daily chart, the index has faced repeated selling pressure near the 26,200; a sustained move above this level may pave the way for the index to inch toward fresh higher levels.

Key Indices Update

| INDEX     | CLOSE    | CHANGE (%) |
|-----------|----------|------------|
| NIFTY     | 26013.45 | 0.40       |
| SENSEX    | 84950.95 | 0.46       |
| BANKNIFTY | 58962.70 | 0.76       |
| INDIA VIX | 11.78    | -1.26      |

FII STATISTICS


FII F&O Data

| Sector        | Buy/Sell | Change in OI |
|---------------|----------|--------------|
| Index Futures | 72.97    | 1.94%        |
| Index Options | -5536.13 | 6.03%        |
| Stock Futures | -924.89  | 0.57%        |
| Stock Options | -133.16  | 2.99%        |

FII & DII Cash Segment (Rs. In Crore)

| Category | Amount  | MTD    | YTD     |
|----------|---------|--------|---------|
| FII      | 442.17  | -13211 | -123431 |
| DII      | 1465.86 | 42817  | 485267  |

FII Activity in Index Future



\*Amt in Crores\*


NIFTY 50 HIGH DELIVERY STOCKS

| SYMBOL    | DELIVERABLE QTY | CHG IN DLY RATIO VS PREV DAY | % CHG IN TRD QTY OVER PREV DAY |
|-----------|-----------------|------------------------------|--------------------------------|
| TATASTEEL | 14370278        | 6.02                         | -26.45                         |
| ETERNAL   | 13558960        | -11.47                       | -28.75                         |
| HDFCBANK  | 12483495        | -5.4                         | -13.98                         |
| BEL       | 7272168         | 4.75                         | -11.71                         |
| POWERGRID | 7219582         | 14.22                        | -4.11                          |
| ICICIBANK | 5884501         | 7.54                         | -20.98                         |
| INFY      | 4894475         | 3.32                         | -18.78                         |
| ITC       | 4851834         | -25.95                       | -87.73                         |
| SBIN      | 4733813         | -0.52                        | -32.79                         |
| JIOFIN    | 4672854         | 7.89                         | -35.1                          |


## NIFTY

|                   |                |
|-------------------|----------------|
| Nifty             | 26060.10       |
| OI (In contracts) | 240805         |
| CHANGE IN OI (%)  | -1.54          |
| PRICE CHANGE (%)  | 0.42           |
| IMPLICATION       | SHORT COVERING |

### NIFTY (CLOSE VS OI)



### NIFTY OPTION CHAIN




### Long Buildup

| Symbol   | Price  | Price % | OI      | OI %  |
|----------|--------|---------|---------|-------|
| ANGELONE | 2854.9 | 3.72    | 3168250 | 14.55 |
| PGEL     | 582.55 | 0.41    | 9398900 | 5.60  |
| SIEMENS  | 3245.6 | 4.80    | 2689500 | 5.21  |
| CDSL     | 1637.1 | 0.44    | 8436475 | 4.32  |
| NUVAMA   | 7393.5 | 0.63    | 339150  | 4.31  |


## BANKNIFTY

|                   |              |
|-------------------|--------------|
| Banknifty         | 59027.40     |
| OI (In contracts) | 49227        |
| CHANGE IN OI (%)  | 0.91         |
| PRICE CHANGE (%)  | 0.65         |
| IMPLICATION       | LONG BUILDUP |

### BANKNIFTY (CLOSE VS OI)



### BANKNIFTY OPTION CHAIN



### Short Buildup

| Symbol    | Price  | Price % | OI       | OI %  |
|-----------|--------|---------|----------|-------|
| TMPV      | 372.4  | -5.21   | 65186400 | 21.86 |
| GLENMARK  | 1876   | -1.39   | 13602375 | 20.03 |
| ZYDUSLIFE | 935.25 | -1.07   | 10028700 | 4.45  |
| INOXWIND  | 146.61 | -1.78   | 68041240 | 4.29  |
| KAYNES    | 6267.5 | -1.33   | 1479600  | 3.66  |

### Top 10 High PCR Ratio Stocks

| SCRIP      | PUT       | CALL      | P/C RATIO |
|------------|-----------|-----------|-----------|
| CANBK      | 149526000 | 117524250 | 1.27      |
| PGEL       | 9034200   | 7340900   | 1.23      |
| ANGELONE   | 2753500   | 2313250   | 1.19      |
| VOLTAS     | 5736375   | 4849125   | 1.18      |
| NATIONALUM | 41216250  | 36817500  | 1.12      |
| MUTHOOTFIN | 5727150   | 5162850   | 1.11      |
| PETRONET   | 15930000  | 14549400  | 1.09      |
| AUROPHARMA | 4953850   | 4593600   | 1.08      |
| AUBANK     | 6597000   | 6387000   | 1.03      |
| BPCL       | 19680875  | 19033075  | 1.03      |

### Top 10 Low PCR Ratio Stocks

| SCRIP      | PUT       | CALL      | P/C RATIO |
|------------|-----------|-----------|-----------|
| SHREECEM   | 59150     | 191175    | 0.31      |
| NESTLEIND  | 2046000   | 6143000   | 0.33      |
| ONGC       | 18456750  | 55271250  | 0.33      |
| TATASTEEL  | 120147500 | 351450000 | 0.34      |
| GMRAIRPORT | 44319150  | 127572750 | 0.35      |
| BLUESTARCO | 978575    | 2681250   | 0.36      |
| FORTIS     | 3972650   | 10927500  | 0.36      |
| KAYNES     | 872500    | 2409600   | 0.36      |
| DELHIVERY  | 11806750  | 31531700  | 0.37      |
| PAGEIND    | 65745     | 175695    | 0.37      |

**NIFTY 50 SUPPORT-RESISTANCE LEVELS**

| SYMBOL     | R1   | R2   | PP   | S1   | S2   |
|------------|------|------|------|------|------|
| ADANIENT   | 2496 | 2520 | 2460 | 2436 | 2400 |
| ADANIPORTS | 1522 | 1531 | 1515 | 1506 | 1499 |
| APOLLOHOSP | 7519 | 7546 | 7482 | 7455 | 7418 |
| ASIANPAINT | 2905 | 2933 | 2891 | 2863 | 2848 |
| AXISBANK   | 1261 | 1272 | 1252 | 1242 | 1232 |
| BAJAJ-AUTO | 9065 | 9161 | 8958 | 8862 | 8755 |
| BAJAJFINSV | 2090 | 2100 | 2074 | 2064 | 2048 |
| BAJFINANCE | 1037 | 1044 | 1029 | 1021 | 1013 |
| BEL        | 429  | 433  | 427  | 423  | 420  |
| BHARTIARTL | 2124 | 2135 | 2115 | 2104 | 2095 |
| CIPLA      | 1542 | 1548 | 1536 | 1530 | 1524 |
| COALINDIA  | 390  | 392  | 389  | 388  | 386  |
| DRREDDY    | 1248 | 1255 | 1244 | 1238 | 1234 |
| EICHERMOT  | 6868 | 6927 | 6765 | 6706 | 6603 |
| ETERNAL    | 313  | 316  | 307  | 304  | 298  |
| GRASIM     | 2804 | 2814 | 2791 | 2781 | 2768 |
| HCLTECH    | 1613 | 1620 | 1600 | 1592 | 1579 |
| HDFCBANK   | 1002 | 1006 | 994  | 990  | 982  |
| HDFCLIFE   | 777  | 783  | 773  | 767  | 762  |
| HINDALCO   | 813  | 817  | 808  | 804  | 799  |
| HINDUNILVR | 2438 | 2449 | 2431 | 2420 | 2413 |
| ICICIBANK  | 1384 | 1388 | 1380 | 1376 | 1372 |
| INDIGO     | 5925 | 5964 | 5891 | 5852 | 5818 |
| INFY       | 1516 | 1524 | 1504 | 1495 | 1484 |
| ITC        | 410  | 412  | 409  | 407  | 405  |

| SYMBOL     | R1    | R2    | PP    | S1    | S2    |
|------------|-------|-------|-------|-------|-------|
| JIOFIN     | 316   | 319   | 314   | 311   | 309   |
| JSWSTEEL   | 1181  | 1187  | 1174  | 1169  | 1162  |
| KOTAKBANK  | 2120  | 2136  | 2106  | 2090  | 2077  |
| LT         | 4047  | 4061  | 4024  | 4009  | 3986  |
| M&M        | 3768  | 3796  | 3729  | 3701  | 3662  |
| MARUTI     | 15966 | 16046 | 15825 | 15745 | 15604 |
| MAXHEALTH  | 1138  | 1150  | 1116  | 1103  | 1081  |
| NESTLEIND  | 1279  | 1287  | 1272  | 1264  | 1257  |
| NTPC       | 332   | 333   | 330   | 329   | 327   |
| ONGC       | 250   | 252   | 249   | 248   | 247   |
| POWERGRID  | 275   | 276   | 273   | 272   | 270   |
| RELIANCE   | 1526  | 1533  | 1521  | 1515  | 1509  |
| SBILIFE    | 2010  | 2017  | 2004  | 1996  | 1991  |
| SBIN       | 977   | 980   | 974   | 970   | 967   |
| SHRIRAMFIN | 831   | 840   | 821   | 811   | 802   |
| SUNPHARMA  | 1770  | 1776  | 1762  | 1756  | 1748  |
| TATACONSUM | 1188  | 1197  | 1175  | 1166  | 1152  |
| TATASTEEL  | 175   | 176   | 174   | 173   | 172   |
| TCS        | 3123  | 3138  | 3103  | 3088  | 3069  |
| TECHM      | 1462  | 1470  | 1449  | 1442  | 1429  |
| TITAN      | 3886  | 3903  | 3860  | 3844  | 3818  |
| TMPV       | 380   | 388   | 372   | 364   | 356   |
| TRENT      | 4430  | 4444  | 4406  | 4392  | 4368  |
| ULTRACEMCO | 11870 | 11935 | 11825 | 11760 | 11715 |
| WIPRO      | 246   | 247   | 244   | 244   | 242   |

## Research Team

| Name                     | Email ID                                                                           |
|--------------------------|------------------------------------------------------------------------------------|
| <i>Ajit Mishra</i>       | <a href="mailto:ajit.mishra@religare.com">ajit.mishra@religare.com</a>             |
| <i>Abhijeet Banerjee</i> | <a href="mailto:abhijeet.banerjee@religare.com">abhijeet.banerjee@religare.com</a> |
| <i>Gaurav Sharma</i>     | <a href="mailto:gauravsharma2@religare.com">gauravsharma2@religare.com</a>         |
| <i>Ashwani Harit</i>     | <a href="mailto:ashwani.harit@religare.com">ashwani.harit@religare.com</a>         |
| <i>Divya Parmar</i>      | <a href="mailto:divya.parmar@religare.com">divya.parmar@religare.com</a>           |
| <i>Rajan Gupta</i>       | <a href="mailto:rajan.gupta1@religare.com">rajan.gupta1@religare.com</a>           |
| <i>Vivek Chandra</i>     | <a href="mailto:vivek.chandra@religare.com">vivek.chandra@religare.com</a>         |
| <i>Himanshu Gupta</i>    | <a href="mailto:himanshu.gupta1@religare.com">himanshu.gupta1@religare.com</a>     |
| <i>Vishvajeet Singh</i>  | <a href="mailto:vishvajeet.singh1@religare.com">vishvajeet.singh1@religare.com</a> |

## Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

**Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:**

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

| S. No. | Statement                                                                                                                                                                                                                                                   | Answer |    |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----|
|        |                                                                                                                                                                                                                                                             | Yes    | No |
|        | I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]                                                                                                          |        | No |
|        | I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance? |        | No |
|        | I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?                                                                                          |        | No |
|        | I/we have received any compensation from the subject company in the past twelve months?                                                                                                                                                                     |        | No |
|        | I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?                                                                                                                                            |        | No |
|        | I/we have received any compensation for brokerage services from the subject company in the past twelve months?                                                                                                                                              |        | No |
|        | I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?                                                                                                              |        | No |
|        | I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?                                                                                                                       |        | No |
|        | I/we have served as an officer, director or employee of the subject company?                                                                                                                                                                                |        | No |
|        | I/we have been engaged in market making activity for the subject company?                                                                                                                                                                                   |        | No |

Nature of Interest if answer to F(a) above is Yes: .....

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

| SS. No. | Name(s) of RA. | Signatures of RA | Serial Question of question which the signing RA needs to make a separate declaration / answer | Yes | No |
|---------|----------------|------------------|------------------------------------------------------------------------------------------------|-----|----|
|         |                |                  |                                                                                                |     |    |
|         |                |                  |                                                                                                |     |    |

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

*No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results*